weight loss, Food and Drug Administration

Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
The weight loss drug dilemma no one wants to talk about
GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most Americans.
Here's why researchers think most people stop taking weight loss drugs within a year
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
Doctor weighs in on controversial weight loss drug commercial
The ad from the telehealth company Hims & Hers promoted the company’s compounded weight loss drugs. The ad portrayed the obesity epidemic as a rigged game because of the greedy health care system. Dr.
What is compounded semaglutide? All you need to know about the weight loss drugs Hims & Hers is selling
Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or side effect disclosures. These compounded drugs, unlike generics, are not regulated or clinically tested by the FDA,
Superbowl Ad Sparks A Healthy Controversy About Medication Safety
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Medscape1d
Paying For GLP-1s: If Medicare Starts, Will Other Insurers Follow Suit?
If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...
WHYY1d
After success with weight loss GLP-1 drugs, IBX patients face high costs after insurer drops coverage for obesity
Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.
Does Medicare Cover Ozempic?
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Hosted on MSN1d
Weight Loss At A Cost: Study Reveals Link Between Ozempic And Vision Loss
A recent study suggests a potential link between Ozempic and vision loss, particularly non-arteritic anterior ischemic optic ...
Super Bowl ad sparks controversy over cut-rate Wegovy alternative
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
Modern Healthcare10d
Digital health companies pitch employers on cutting GLP-1 costs
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
Diet drug boom weighs heavily on state budgets
The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...